Nilotinib Eg

Nilotinib, the active ingredient in Nilotinib Eg, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is employed in the treatment of chronic myeloid leukemia in adult patients, targeting the BCR‑ABL fusion protein that drives disease progression.

GNH USA supplies Nilotinib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Nilotinib is indicated for chronic myeloid leukemia, a malignancy driven by BCR‑ABL tyrosine kinase activity.

- Chronic phase CML: achieves deeper molecular and cytogenetic responses, improving long‑term disease control. - Accelerated phase CML: reduces disease progression and prolongs survival when used as first‑line therapy. - CML resistant or intolerant to prior tyrosine kinase inhibitors: provides an effective alternative treatment option.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash

Serious or Rare Side Effects: - QT interval prolongation, which can lead to arrhythmias - Pancreatitis, presenting with abdominal pain and elevated enzymes - Severe hepatic toxicity, indicated by marked transaminase elevation

When prescribing nilotinib, clinicians should observe several precautionary measures to minimize risk.

- Cardiac monitoring: obtain baseline ECG and repeat periodically because of QT prolongation risk. - Hepatic assessment: check liver function tests before initiation and during therapy. - Hematologic surveillance: monitor complete blood count for neutropenia or thrombocytopenia. - Concomitant QT‑prolonging drugs: avoid or adjust therapy to reduce additive arrhythmic risk. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Nilotinib interacts with several medicines; understanding the level of interaction guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase nilotinib plasma concentrations. - QT‑prolonging agents (e.g., amiodarone, sotalol): additive risk of serious arrhythmias. - Antacids containing aluminum or magnesium: significantly reduce nilotinib absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure and reduce efficacy. - Warfarin: nilotinib can alter INR; frequent coagulation monitoring is advised. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): increased risk of myopathy; consider dose adjustment or alternative statin.